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Introduction
Sotalol is the prototype class III agent that combines
^-blocking properties with the propensity to prolong
the effective refractory period by lengthening the action
potential duration. A review of clinical trials demon-
strates that sotalol is an effective treatment for unsus-
tained and sustained ventricular tachyarrhythmias. It is
also active against several supraventricular
arrhythmias. Sotalol is safe and generally well toler-
ated; most of the adverse effects experienced with its
use are related to its /^-blocking activity. However,
sotalol has been associated with life-threatening pro-
arrhythmias, including torsade de pointes, although
the incidence of this adverse effect is low, varying
between 1.8 and 3% in the clinical trials conducted to
date [1-3]. To our knowledge, the occurrence of sota-
lol-induced torsade de pointes has never been reported
before in haemodialysis (HD) patients. We report here
three HD patients who underwent cardiopulmonary
resuscitation for torsade de pointes and cardiopulmon-
ary arrest under low-dosage sotalol therapy.
Case reports
Case 1. A 53-year-old female patient had had recurrent
pulmonary infections because of bronchiectasis of the
lower lobes from the age of 19. HD was started in
1983 because of end-stage renal disease (ESRD) due
to secondary renal amyloidosis. In November 1992, a
resection of the lingula was performed. Postoperatively
sotalol was started in a low dosage of 2 x 40 mg/day
for recurrent supraventricular tachyarrhythmias. On
the second day, the patient underwent mechanical
cardiopulmonary resuscitation because of torsade de
pointes. The ECG showed a prolonged corrected QTc
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interval of 550 ms. Sotalol was stopped and magnesium
sulphate was given; the QTc interval normalized and
the patient remained in a stable sinus rhythm of 70/min.
Case 2. A 78-year-old male patient with a known
hypertensive and coronary heart disease had been on
HD since 1979 because of ischaemic nephropathy. In
July 1995 he developed intermittent supraventricular
tachyarrhythmias; because of digoxin incompatibility,
sotalol was given in a dosage of 2 x 40 mg/day without
supplemental dosage after HD. One month later he
was hospitalized because of acute gastrointestinal
bleeding under aspirin and indomethacin. During the
first 3 days he needed daily blood transfusions and
endoscopic haemostasis because of recurrent bleeding.
On the third day, torsade de pointes with haemo-
dynamic compromise occurred twice (Figure 1) but
responded promptly to cardioversion and magnesium
sulphate infusion. The ECG showed a bradycardia of
50/min and a slightly prolonged QTc of 480 ms. Sotalol
was replaced by atenolol and the patient recovered
uneventfully.
Case 3. A 73-year-old female patient with hyperten-
sive, valvular and coronary heart disease had been on
CAPD, then HD since 1979 because of analgesic-
associated nephropathy. In May 1995 she underwent
parathyroidectomy for secondary hyperparathyroid-
ism. Postoperatively acute atrial fibrillation occurred,
but could be controlled with digoxin plus sotalol.
Digoxin was discontinued after 1 more day, and the
patient remained on sotalol 2 x 40 mg/day. One week
later, she had a cardiopulmonary arrest, which was
successfully managed by chest compression. The
ECG immediately after cardiopulmonary resuscitation
showed a bradycardia of 44-52/min, with a QTc of
540 ms. After sotalol was stopped, the heart rate and
QTc interval normalized during the following 3 days.
Discussion
The side-effects of sotalol are related either to its /?-
blocking properties or to its propensity to lengthen the
QT interval. Adverse reactions due to /?-adrenergic
receptor blockade are similar to those associated
with conventional /?-adrenergic antagonists. How-
ever, aggravation of congestive heart failure by sotalol
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Fig. 1. Electrocardiogram demonstrating torsade de pointes. It is readily apparent that a long pause precedes the sinus beat which triggers 
a run of polymorphic ventricular tachycardia. The tachycardia is characterized by periodic shifts in the QRS axis and in its amplitude. 
is less frequent than might be expected with a P- 
adrenergic antagonist. 
The most dangerous effect of antiarrhythmic drugs 
is aggravation of pre-existing arrhythmias or the pro- 
vocation of new arrhythmias. The drugs that prolong 
the action potential duration may cause torsade de 
pointes, a polymorphic ventricular tachycardia associ- 
ated with an exaggerated prolongation of the QT 
interval. Many cases of sotalol-induced torsade de 
pointes have been associated with drug overdose or 
predisposing factors, such as bradycardia, hypokalae- 
mia, or concomitant use of drugs that prolong repolar- 
ization [4-61. A recent review of data from controlled 
trials of sotalol in a total of 3257 patients reported 
proarrhythmic events in 141 (4.3%) patients. Of these, 
78 (2.4%) had torsades de pointes, which were more 
prevalent in patients with congestive heart failure and 
low ejection fraction. Torsade de pointes were observed 
early in the course of the treatment and their occur- 
rence was related to. dose [I].  Most studies have 
reported control of arrhythmia with daily doses 
between 160 and 640 mg in patients with normal renal 
function. With doses ranging from 160 to 640 mg/d, 
the QT interval is prolonged by 40-100 ms. 
Exaggerated prolongation results in a predisposition 
to torsade de pointes. Although there are no data from 
controlled studies, the current recommendation is that 
sotalol therapy should be discontinued at a maximal 
QTc interval of 500 ms [7]. 
Oral administered sotalol is almost completely 
absorbed and does not undergo first-pass metabolism 
in the liver, resulting in a bioavailability of 90-100%; 
85-90% of the drug is excreted unchanged in the urine, 
the mean elimination half-life being 8 + 3 h in patients 
with normal renal function. In ESRD the elimination 
half-life is increased to 41 h, so that a dose reduction 
to 25% of the normal dosage is recommended. 
However, sotalol is effectively removed by haemo- 
dialysis (HD), and a supplemental dose of 80 mg is 
currently recommended after each H D  [7,8]. 
Our three patients were all treated with 80 mg sotalol 
daily, without drug supplementation after HD, which 
implies a low dosage of sotalol. Nonetheless cardiopul- 
monary arrest occurred 1-14 days after the drug had 
been started. In all three patients, the QTc interval at 
the time of cardiopulmonary resuscitation was over 
480 ms. Although torsade de pointes had been docu- 
mented in patients 1 and 2 only, the excessive bradycar- 
dia and prolongation of the QTc interval in patient 3 
makes the same diagnosis very probable. All patients 
had normal electrolytes at the time of cardiopulmonary 
resuscitation, and none had concomitant therapy with 
any drug known to prolong cardiac repolarization. 
Patients 2 and 3, however, had a reduced cardiac 
ejection fraction. 
To our knowledge, this life-threatening complication 
of sotalol has never been reported before in H D  
patients. Because of our own experience, we advise 
extreme caution in the indications and use of sotalol 
in that special patient population. A daily dose of 
40 mg schould not be exceeded in the first days, and 
daily ECG controls are warranted in the acute titration 
phase in order to register a possible excessive prolonga- 
tion of the QTc interval, and stop sotalol medication 
on time. 
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Editor's note 
Please see also the Editorial Comment by BIhrle (pp. 944-946 in 
this issue). 
